Email: Huange78@163.com

Introduction: 
I was born in Anhui, China and I received BS degree from Wannan Medical College in 2017. I'm currently a PhD graduatein the research group of Professor Li at East China University of Science and Technology and major in pharmacology.

Education Background:
2017-2023, Ph.D., Pharmacy, East China University Of Science And Technology.
2013-2017, B.E., Pharmaceutical Preparations, Wannan Medical College.

Publication:

[1] Huan Ge^†, Caolin Wang, Chaoquan Tian, Yanyan Diao, Wanqi Wang, Xiangyu Ma, Jian Zhang, Honglin Li, Zhenjiang Zhao, Lili Zhu*. Efficacy of WWQ-131, a highly selective JAK2 inhibitor, in mouse models of myeloproliferative neoplasms. Biomed. Pharmacother. 2022, 156 : 113884.

[2]Wanqi Wang^†, Yanyan Diao^†, Wenjie Li^†, Yating Luo, Tingyuan Yang, Yuyu Zhao, Tiantian Qi, Fangling Xu, Xiangyu Ma, Huan Ge, Yingfan Liang, Zhenjiang Zhao, Xin Liang, Rui Wang, Lili Zhu*, Honglin Li*, Yufang Xu*. Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus Kinase 2. Bioorg. Med. Chem. Lett. 2019. 29(12): 1507-1513.

[3] Dandan Liu^†, Huan Ge^†, Fangling Xu^†, Yufang Xu, Wenjun Liu, Honglin Li a, Lili Zhu*, Yanyan Diao*, Zhenjiang Zhao*. Design, synthesis and SAR study of 2-aminopyridine derivatives as potent and selective JAK2 inhibitors.Chin. J. Chem. 2021. 33(6): 2069-2974.

[4] Yanling Wang^†, Huan Ge^†, Disha Wang, Huan He, Lu Li, Yanyan Diao, Zihao Shen, Lili Zhu, Shiliang Li, Zhenjiang Zhao*, Honglin Li*. Design and synthesis of a series of novel macrocycle Janus kinase 2 inhibitors. Chin. J. Chem. 2019, 37(12): 1259-1263.

[5] Xiangyu Ma^†, Yanyan Diao^†, Huan Ge^†, Fangling Xu, Lili Zhu*, Zhenjiang Zhao*, Honglin Li*. Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors. Bioorg. Med. Chem. Lett., 2020. 30(8): 127048.

[6] Bingqian Li^†, Lin Wang^†, Huan Ge^†, Xianglei Zhang, Penxuan Ren, Yu Guo, Wuyan Chen, Jie Li, Wei Zhu, Wenzhang Chen, Lili Zhu*, Fang Bai*. Identification of Potential Binding Sites of Sialic Acids on the RBD Domain of SARS-CoV-2 Spike Protein. Front Chem.2021, 9: 659764.

[7] Pengxuan Ren^†, Weijuan Shang^†, Wanchao Yin^†, Huan Ge^†, Lin Wang^†, Xianglei Zhang, Bingqian Li, Honglin Li, Yechun Xu, Eric H Xu, Hualiang Jiang, Lili Zhu*, Leike Zhang*, Fang Bai*. A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors. Acta Pharmacol. Sin. 2022, 43(2): 483-493.

[8] Lin Wang^†, Yan Wu^†, Sheng Yao^†, Huan Ge^†, Ya Zhu, Kun Chen, Wenzhang Chen, Yi Zhang, Wei Zhu, Hongyang Wang, Yu Guo, Peixiang Ma, Pengxuan Ren, Xianglei Zhang, Huiqiong Li, Mohammad A Ali, Wenqing Xu, Hualiang Jiang, Leike Zhang*, Lili Zhu*, Yang Ye*, Weijuan Shang*, Fang Bai*. Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein. Acta Pharmacol Sin. 2022, 43(4):788-796.